Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K

Open source

DOI
10.1007/s10147-025-02837-8
Published
2025 Oct
Container
International journal of clinical oncology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10147-025-02837-8,
  title = {Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.},
  author = {Morimoto K and Yamada T and Furuya N and Tanaka H and Yoshimura A and Oba T and Hibino M and Fukuda T and Goto Y and Nakao A and Ogusu S and Okazaki Y and Harada T and Ota T and Masubuchi K and Mikami K and Hata T and Matsumoto S and Honda R and Date K and Chihara Y and Takayama K},
  year = {2025},
  journal = {International journal of clinical oncology},
  doi = {10.1007/s10147-025-02837-8},
  url = {https://doi.org/10.1007/s10147-025-02837-8}
}

RIS

TY  - JOUR
TI  - Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
AU  - Morimoto K
AU  - Yamada T
AU  - Furuya N
AU  - Tanaka H
AU  - Yoshimura A
AU  - Oba T
AU  - Hibino M
AU  - Fukuda T
AU  - Goto Y
AU  - Nakao A
AU  - Ogusu S
AU  - Okazaki Y
AU  - Harada T
AU  - Ota T
AU  - Masubuchi K
AU  - Mikami K
AU  - Hata T
AU  - Matsumoto S
AU  - Honda R
AU  - Date K
AU  - Chihara Y
AU  - Takayama K
PY  - 2025
JO  - International journal of clinical oncology
DO  - 10.1007/s10147-025-02837-8
UR  - https://doi.org/10.1007/s10147-025-02837-8
ER  - 

APA

K, M., T, Y., N, F., H, T., A, Y., T, O., M, H., T, F., Y, G., A, N., S, O., Y, O., T, H., T, O., K, M., K, M., T, H., S, M., R, H., K, D., Y, C., & K, T. (2025). Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.. International journal of clinical oncology. https://doi.org/10.1007/s10147-025-02837-8

Source records